Latest News and Press Releases

NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...

NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...

Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with...

NEWTOWN, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...

NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...

NEWTOWN, Pa., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

NEWTOWN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting...

NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...

Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone Rigosertib’s...